TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES
NWCJV Donka, R Popatb, L Rosiolc, B Besemerd, JM Lopeze, D Trancuccif, R Veronag, T Stephensong, K Chastainf, N Bahlish
a Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
b University College London Hospitals, NHS Foundation Trust, London, United Kingdom
c Hospital Clínic de Barcelona (IDIBAPS), Barcelona, Spain
d University of Tuebingen, Tuebingen, Germany
e Hematología Hospital 12 de Octubre, Madrid, Spain
f Janssen Research & Development, Raritan, United States
g Janssen Research & Development, Spring House, United States
h Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
Lido
1744
Vezesque se leu este artigo
520
Total PDF
1224
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 13 | 5 | 18 |
| 2025 5 | 79 | 13 | 92 |
| 2025 4 | 55 | 17 | 72 |
| 2025 3 | 66 | 13 | 79 |
| 2025 2 | 64 | 29 | 93 |
| 2025 1 | 57 | 30 | 87 |
| 2024 12 | 54 | 18 | 72 |
| 2024 11 | 73 | 26 | 99 |
| 2024 10 | 81 | 47 | 128 |
| 2024 9 | 91 | 30 | 121 |
| 2024 8 | 61 | 36 | 97 |
| 2024 7 | 58 | 30 | 88 |
| 2024 6 | 68 | 41 | 109 |
| 2024 5 | 62 | 32 | 94 |
| 2024 4 | 78 | 35 | 113 |
| 2024 3 | 28 | 16 | 44 |
| 2024 2 | 61 | 18 | 79 |
| 2024 1 | 60 | 16 | 76 |
| 2023 12 | 49 | 23 | 72 |
| 2023 11 | 58 | 37 | 95 |
| 2023 10 | 8 | 8 | 16 |
Mostrar tudo
